To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention. A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy. GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities. GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.
28 March 2025 in Journal of Gastrointestinal and Liver Diseases
Irritable Bowel Syndrome (IBS) is a prevalent functional gastrointestinal disorder that significantly impacts the quality of life and the healthcare system. Beyond well-established symptoms such as recurrent abdominal pain and altered bowel habits, emerging evidence highlights a crucial yet underexplored aspect of cognitive dysfunction in patients suffering from IBS. This review aims to investigate the potential mechanisms linking IBS to cognitive dysfunction, emphasizing the role of the gut-brain axis and its biological and psychosocial determinants. A literature review was conducted using major medical databases, including Pubmed and Scopus, to identify relevant studies published in the last decade, focusing on clinical and experimental research assessing cognitive impairment in IBS patients. The review underscores the need for increased clinical recognition of cognitive dysfunction in IBS by highlighting the cognitive dysfunction in IBS patients with a focus on pathogenesis from disturbances in gut microbiota, inflammation, altered neurotransmitter levels, and psychological stress with various treatment modalities targeting these pathways, including probiotics, cognitive-behavioural therapy, and pharmacological interventions, showing promising results in mitigating cognitive symptoms.
24 September 2025 in Journal of Parkinson’s Disease
Parkinson's disease (PD) is a rapidly developing neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the basal ganglia of the brain. Its prevalence is estimated to exceed 1.2 million cases in the United States by 2030. Emerging evidence suggests that PD may originate in the gut and hence is linked to gastrointestinal (GI) dysfunctions such as inflammatory bowel disease and GI cancers. Colorectal cancer (CRC) is one of the most common cancers seen worldwide. It shares several risk factors with PD, including advancing age, male gender, genetic predispositions, and environmental exposures. Although these shared factors indicate a possible correlation, the studies evaluating this relationship have suggested inconsistent results. Some research proposes an increased risk of CRC in PD patients, potentially due to overlapping genetic and inflammatory pathways. Alternatively, others argue an inverse relationship due to opposing underlying mechanisms of neuro degeneration in PD and cellular proliferation in CRC. This narrative review explores the intricate relationship between PD and CRC and seeks to understand how neurodegenerative and malignant diseases may overlap.
Anorexia nervosa (AN) is a severe psychiatric disorder with profound cardiovascular consequences, including QT interval prolongation and bradycardia. These abnormalities contribute to an increased risk of life-threatening arrhythmias, sudden cardiac death, and long-term cardiac dysfunction. Although electrolyte imbalances and malnutrition are also recognized as key contributors, the precise...
29 October 2024 in Turkish Journal of Internal Medicine
Sarcoidosis is a multi-organ granulomatous disease of uncertain origin, characterized by the formation of non-necrotizing granulomas in various organs, including the heart. Cardiac involvement in sarcoidosis is rare, with approximately 5% of sarcoidosis patients developing clinically apparent cardiac disease, which is associated with significant morbidity and mortality. Genetically predisposed individuals develop granuloma in myocardium musculature, leading to aberrant conduction of cardiac impulses and the development of various arrhythmias. Common arrhythmias range from atrial fibrillation to ventricular tachycardia and can lead to sudden cardiac death because of ventricular fibrillation. The diagnostic challenge results from high specificity but rather limited sensitivity of endomyocardial biopsy, which is the gold standard diagnostic test, making advanced imaging techniques, such as cardiac magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography, crucial for early detection. Management involves a complex approach with immunosuppression, antiarrhythmic medications, and catheter ablation, often supplemented by implantable cardioverter-defibrillators to prevent sudden cardiac death. In cardiac sarcoidosis, ventricular arrhythmias are common and cause high mortality. Timely intervention and management are crucial for a better prognosis. The disease's growing prevalence requires further research on refining early detection techniques and developing efficient treatment strategies for these high-risk patients. This review focuses on the etiopathogenesis of arrhythmias in cardiac sarcoidosis, diagnosis, and effective management strategies.
1. AF is the most common sustained cardiac arrhythmia in adults, affecting an estimated 5–6 million individuals in the United States [1]. AF significantly increases the risk of thromboembolic strok...